Español
Questions About Cancer? 1-800-4-CANCER
  • Email

Clinical Trials Search Results

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 41 for your search:
Drug:  therapeutic autologous lymphocytes
Find trials that include:  Any drugs shown
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 20 to 79
Sponsor: Other
Protocol IDs: IVY02, NCT01024530

2.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: CL-CA-P01-00-US, 2014-000544-15, NCT01875653

3.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 65 and under
Sponsor: NCI, Other
Protocol IDs: 1409.00, NCI-2010-00130, P30CA015704, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803

4.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI, Other
Protocol IDs: 06-138, MSKCC-06138, NCT00466531

5.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 80 and under
Sponsor: Other
Protocol IDs: 23637-MULTIPRAT, MultiPRAT, NCT00840853

6.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: ARL-GT 2005, NCT00858793

7.

Phase: Phase II, Phase I
Type: Supportive care
Status: Active
Age: 45 to 70
Sponsor: Other
Protocol IDs: BT06-07, 2008-A01248-47, NCT01089387

8.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110013, 11-C-0013, NCT01218867

9.

Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 21 and under
Sponsor: Other
Protocol IDs: Re-MATCH, W81XWH-10-1-0089, CDMRP-PRO93877, NCT01326104

10.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: UPCC 01411, NCT01352286

11.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: D-00272-CT2014001, NCT01621724

12.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 1 to 26
Sponsor: Other
Protocol IDs: PLAT-02, NCT02028455

13.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: MC01/21/13, 2013/00566, NCT02030561

14.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 19273-4SCAR, NCT02247609

15.

Phase: Phase II, Phase I
Type: Treatment
Status: Active
Age: 6 months to 80 years
Sponsor: Other
Protocol IDs: 2014/00584, NCT02315118

16.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 030040, 03-C-0040, NCI-03-C-0040, NCI-5762, 5762, NCT00053170, NCT00048893

17.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: XT009, NCT00081783

18.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: Over 18
Sponsor: Other
Protocol IDs: MS269- HMO-CTIL, NCT00604136

19.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: LFNK, 2009-017829-19, NCT01329354

20.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: 110260, 11-C-0260, NCT01468818

21.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2013-05, NCT01884688

22.

Phase: Phase II
Type: Treatment
Status: Active
Age: 20 to 80
Sponsor: Pharmaceutical / Industry
Protocol IDs: ILC-IIT-04, NCT01897610

23.

Phase: Phase II
Type: Treatment
Status: Approved-not yet active
Age: 18 and over
Sponsor: Other
Protocol IDs: 2012-1055, R1301, SU2C-AACR-OT 1012, NCT02027935

24.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 13413, NCT02030834

25.

Phase: Phase II
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCC 21413, NCT02030847
1   
New Search